2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

622. Lymphomas: Translational – Non-Genetic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1757 CXCR4 blockade with plerixafor augments CD20×CD3 bispecific antibody therapy in a syngeneic GCB-DLBCL model

Eric Perkey, MD-PhD, Joanna K Chorazeczewski, MS2, Xiufen Chen, PhD3, Reid Shaw, MD4, Yue Qin, PhD5, James Godfrey, MD6, Justin Kline, MD7
1 University of Chicago, CHICAGO, Illinois, United States
2 University of Chicago, CHICAGO, Illinois, United States
3 University of Chicago, CHICAGO, Illinois, United States
4 University of Chicago, CHICAGO, Illinois, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 University of Chicago, CHICAGO, Illinois, United States

Introduction. CD20×CD3 bispecific antibodies (BsAbs) are active in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), but responses are often not durable. Our recent genomic analysis clustered DLBCLs into immune quadrants. The T-cell–depleted GCB-cold quadrant, enriched for GNA13 alterations and a dark zone gene signature (DZsig+), responded poorly to BsAb monotherapy (Tumuluru et al., Blood 2025). Because BsAb killing requires T-cell contact, this poor response may reflect sequestration of lymphoma cells in T-cell–excluded niches. The genetics of GCB-cold DLBCL implicate chemotaxis toward these niches. GNA13 loss-of-function mutations are predicted to enhance chemotaxis toward chemokines such as CXCL12. Conversely, multiple DLBCL cell lines carry recurrent, putatively gain-of-function hotspot mutations in GNAI2, which encodes a Gα subunit that transduces CXCR4 signaling. We therefore hypothesized that CXCR4-dependent retention of lymphoma cells in CXCL12-rich niches limits encounters with BsAb-redirected T cells, and that CXCR4 blockade with plerixafor would enhance BsAb activity.

Methods. tFL-P6 is an aggressive GCB-DLBCL line modeling transformed follicular lymphoma, derived from an Ezh2Y641F; Rosa26LSL.BCL2.IRES.GFP GEMM and engineered to express luciferase, which has previously been used to test BsAbs (Isshiki et al., Cancer Cell 2025). Immunocompetent C57BL/6 mice received 5 × 10⁶ tFL-P6 cells IV. On day 5 after inoculation, mice received a murine surrogate of epcoritamab (1:1 format, LALA-PG Fc) as a single 0.25 mg/kg dose, 0.1 mg/kg twice weekly, or vehicle. Plerixafor (10 mg/kg SC) or vehicle was given 1–2 hours before BsAb. Survival and tumor burdern by bioluminescence imaging (BLI) was analyzed across two experiments (n=46). Seperately, blood was sampled 2 hours after plerixafor alone to assess mobilization, and blood and spleen were collected 24 hours after treatment to assess tumor content and T-cell activation; each spleen was split in half, with one half mechanically dissociated and the other collagenase-digested to release stroma-adherent cells.

Results. While a single 0.25 mg/kg dose of BsAb controlled disease in a subset of mice, repeated 0.1 mg/kg dosing did not improve survival compared with untreated controls, despite confirmed T-cell activation at this dose. Adding plerixafor to this subtherapeutic regimen reduced mortality versus BsAb alone (HR 0.13, p=3×10⁻⁴), with median survival of 28 days versus 12.5 days. Plerixafor alone did not alter survival. Five days after treatment, BLI signal increased 48-fold in controls and 41-fold with BsAb alone, but only 9-fold with the combination (p=7×10⁻⁴ versus BsAb alone). Plerixafor was pharmacodynamically active: 2 hours after dosing, blood granulocytes rose from 10% to 25% of live cells. Despite uniform surface CXCR4 expression on lymphoma cells by flow cytometry, plerixafor did not mobilize lymphoma cells into the circulation. At 24 hours, BsAb alone reduced splenic lymphoma burden 17- to 33-fold relative to untreated mice and eliminated circulating non-malignant B cells, confirming target engagement despite no survival benefit. Depletion was deeper when BsAb was combined with plerixafor (66- to 74-fold). After BsAb alone, residual lymphoma cells were enriched in the collagenase-digested fraction, whereas the two fractions were equivalent with the combination. This difference was not explained by T-cell activation (CD69, CD25), T-cell numbers, or BsAb-driven T-cell margination from blood, all of which were comparable between BsAb-treated groups.

Conclusions. In a syngeneic GCB-DLBCL model, priming with plerixafor converted an ineffective CD20×CD3 BsAb regimen into one that more than doubled median survival. Plerixafor alone did not improve survival, so CXCR4 antagonism is not therapeutic on its own. At a dose that mobilized granulocytes, plerixafor neither mobilized lymphoma cells into the circulation nor changed early T-cell activation, indicating an alternative mechanism of action. Residual lymphoma cells were enriched in the collagenase-digested spleen fraction of mice treated with BsAb alone, consistent with a stroma-adherent reservoir that escapes BsAb-mediated killing. Together, these data support a model in which CXCR4 blockade liberates lymphoma cells from protective CXCL12-rich niches, exposing them to BsAb-redirected T cells. Clinically, these findings nominate CXCR4 antagonism as a priming strategy to improve BsAb therapy in lymphoma.

Eric Perkey, MD-PhD: No relevant conflicts of interest to declare.